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Expression of nitric oxide synthase (NOS) has been found to correlate with tumour progression in 
breast cancer, indicating that NO activity may drive malignant growth. Previously we have shown 
that the stress hormone cortisol acts through a nitric oxide synthase (NOS) mediated pathway to 
induce production of nitric oxide (NO), and can induce DNA damage in breast cancer. 
Breast cancer cell lines MCF-7 and MDA-MB-231 as well as the mouse mammary tumour cell line 
66CL4 were exposed to cortisol and levels of intracellular NO were measured using composite 
electrochemical sensors. DNA damage was quantified using immunofluorescence and expression of 
iNOS and metastatic markers VEGF and TWIST were examined using qPCR. An in vivo syngeneic 
breast cancer model was also used to examine the effect of L-NAME, a NOS inhibitor, on tumour 
aggressiveness and metastasis in conjunction with daily restraint stress (2hrs) (n=4/group repeated 
in duplicate).  
Cortisol significantly increased the expression of iNOS, the generation of NO and DNA damage in 
breast cancer cells and this was blocked by the NOS inhibitor L-NAME. A significant increase in VEGF 
and TWIST expression was also observed in response to cortisol. Furthermore, L-NAME also 
significantly reduced primary tumour growth in stressed mice and reduced the number of metastatic 
sites/mouse. Tumour microvasculature (as evidenced by CD31 expression) was significantly 
increased in stressed mice and this was reduced with L-NAME treatment.  
We demonstrated that L-NAME through inhibition of NO signalling is effective in reducing primary 
tumour formation and metastatic potential in stressed mice. This data may have impact for patients 
with breast cancer experiencing extreme stress and further genomic analysis are ongoing.    
 
 
